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Abstract: In many cases of envenoming following snake bite, the snake responsible for the 
accident remains unidentified; this frequently results in difficulty deciding which 
antivenom to administer to the systemically-envenomed victim, especially when only 
monospecific antivenoms are available. Normally the specific diagnosis of snake bite can 
be conveniently made using clinical and laboratory methods. Where clinical diagnosis 
depends upon the recognition of specific signs of envenoming in the patient, laboratory 
diagnosis is based on the changes which occur in envenomed victims including the 
detection of abnormalities in blood parameters, presence/absence of myoglobinuria, 
changes in certain enzyme levels, presence/absence of neurotoxic signs and the detection in 
the blood of specific venom antigens using immunologically-based techniques, such as 
enzyme immunoassay. It is the latter which is the main subject of this review, together with 
the application of techniques currently used to objectively assess the effectiveness of new 
and existing antivenoms, to assess first aid measures, to investigate the possible use of such 
methods in epidemiological studies, and to detect individual venom components. With this 
in mind, we have discussed in some detail how such techniques were developed and how 
they have helped in the treatment of envenoming particularly and in venom research  
in general. 
Keywords: snakebite; clinical diagnosis; laboratory diagnosis; biodetection; antivenom; 
pharmacokinetics; first aid; epidemiology; venom components 
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1. Introduction  
“Slash, suck out the venom and apply a tourniquet”—It was partly to challenge this dangerous 
historical advice that many scientists throughout the world, interested in the treatment of snakebite and 
other venomous bites and stings, united in a common aim of improving diagnosis and treatment. In 
snake bite, it is often difficult for clinicians treating patients to determine the species responsible for 
envenoming, thus making treatment with the correct antivenom more difficult, especially in regions 
where only monospecific antivenoms are available. This was one of the major reasons which inspired 
the development of sensitive assay techniques using immunodiagnostic and other laboratory-based 
methods. Early in investigative studies, it was shown that immunodiagnosis using enzyme immunoassay 
(EIA) or enzyme-linked immunosorbent assay (ELISA) was useful for the identification of the species 
responsible for envenoming and also for the detection of specific venom antibody [1]; this followed the 
detection of venom using radioimmunoassay (RIA) developed by Sutherland’s group in Australia [2,3]. 
Later, this group also used EIA, which proved to be much cheaper than RIA and obviously did not 
require the use of radioisotopes [4]. The method enabled the recognition of accurate diagnostic patterns 
of envenoming by different, sometimes closely related, snake species. Initially, however, a result could 
only be obtained within a matter of hours rendering an urgent requirement for a more rapid test which 
would need to provide a reliable diagnostic result within a few minutes of taking a blood sample from 
the envenomed victim. Only then could the assay system become appropriate for actual early treatment 
of the patient with antivenom. Such a rapid test has been developed in Australia but, unfortunately, this 
is considered too expensive and has problems relating to sensitivity [5]. The value of EIA in the study 
of new and existing antivenoms is that it provides an important objective assessment of antivenom 
efficacy; as studies mentioned in this review demonstrate, it has proved a useful tool in supplementing 
clinical observations following antivenom administration after snake bite. Recent advances in the use 
and development of EIA have added enormously to its use in the field of venom research [6]. The 
value of EIA in evaluating currently available and novel first aid measures may also prove invaluable 
both now and in the future, as well as its application in other aspects of venom research. 
2. Background 
The diagnosis of snake bite or determination of which snake is responsible for envenoming of a 
victim can be conveniently divided into clinical diagnosis and laboratory diagnosis. Clinical diagnosis 
depends upon recognising specific signs of envenoming in the patient. This includes local signs such 
as swelling (Figure 1a,b), blistering (Figure 2d), and local necrosis (Figure 1c,d). More importantly  
for accurate diagnosis, systemic signs, such as haemorrhage (Figure 2b,c,d), incoagulable blood, and 
hypovolaemic shock (Figure 2d), are common mainly in viper bite, whereas neurotoxic signs (Figure 3a) 
occur primarily in elapid bite, and rhabdomyolyis (muscle damage) in sea snake bite (Figure 3b). 
Indeed, the late Alistair Reid, founder of the Venom Research Unit, Liverpool School of Tropical 
Medicine, UK, made many of the original observations pertaining to this, although it should be noted 
that there are exceptions to this rule. For example, some Australian elapid venoms can cause 
haemorrhage and incoagulable blood in addition to neurotoxicity and the venoms of some vipers, such 
as the tropical rattlesnake, Crotalus durissus terrificus, and the berg adder, Bitis atropos, can cause 
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neurotoxic signs in systemically envenomed victims. Local effects, such as necrosis, may occur, 
especially following viper bites, but this tends to be a slightly later manifestation and is not necessarily 
diagnostic (Figure 1c,d). Likewise, some cobras are capable of spitting venom; if this enters the eyes it 
causes a severe local painful conjunctivitis with accompanied swelling (Figure 1b). It should also be 
noted that the presence or absence of fang marks are not diagnostic although the distance between the 
fang marks does provide an indication as to the size of the biting snake; however, the detection of fang 
marks does not necessarily indicate that venom has actually been introduced (Figure 2a). Indeed, in 
about 50% of bites no venom is injected. More detailed information on clinical diagnosis of snake bite 
is provided in a recent review [7]. 
Figure 1. (a) Swelling of hand following a viper bite on the third finger of the left hand. 
Fang marks can be observed (courtesy, Hugh Alistair Reid); (b) Swelling and 
conjunctivitis 4 hours after venom entered the eyes of this individual following a spit by an 
African spitting cobra (Naja nigricollis); (c) Local necrosis following a pit viper bite in 
Peru (courtesy, David Gaus); (d) Amputation in two children as a long-term sequel of pit 
viper (Bothrops atrox) bite in Amazonian Brazil (courtesy, David Alan Warrell). 
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Figure 2. (a) Fang marks and hair tourniquet following a bite by a large Russell’s viper in 
Sri Lanka (courtesy, DA Warrell); (b) Bleeding under the tongue and from the gum 
margins (gingival sulci) caused by viper venom (courtesy, DA Warrell); (c) Bleeding into 
the base of the brain (subarachnoid bleed) following admission to hospital 5 days after a 
viper bite (courtesy, HA Reid); (d) Bleeding into the tissues due to the haemorrhagic effect 
of a viper venom on the blood vessels resulting in hypovolaemic shock. Blistering in the 
region of the bite site with underlying local necrosis is also shown (courtesy, HA Reid). 
 
Figure 3. (a) Ptosis and inability to extrude the tongue (neurotoxic signs) in a victim of 
elapid bite (courtesy, DA Warrell); (b) Rhabdomyolysis (muscle damage) following a bite 
by a sea snake. This movement of the leg is extremely painful. Note the presence of 
myoglobin in the sample of urine by the bedside (arrow) (courtesy HA Reid). 
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Laboratory diagnosis of snake bite is based on the changes which occur in envenomed victims. 
These include the detection of abnormal changes in blood parameters (e.g., incoagulable blood  
(Figure 4a) as examined using the simple bedside 20 min whole blood clotting test, WBCT20  
(Figure 4b) [8–10], dramatic fall in the platelet count, changes in red and white blood cell counts), 
presence/absence of myoglobinuria, changes in certain enzyme levels (such as creatine phosphokinase) 
and the detection in the blood of the victims of specific venom antigens (biodetection methods using 
immunologically-based techniques). It is the latter point which is one of the main subjects of this 
review together with the application of other immunological techniques for use in venom research such 
as the objective assessment of the effectiveness of new and existing antivenoms, the assessment of first 
aid measures, the possible use of such methods in epidemiological studies and the immunodetection of 
individual venom components. 
Figure 4. (a) Incoagulable blood from a patient with envenoming by a viper. A normal clot 
is shown on the left; (b) The 20 min Whole Blood Clotting Test (WBCT20) for simple 
bedside detection of venom-induced coagulopathy. 
 
3. Biodetection Methods Considered for Use in Venom Research 
Over the years a number of immunologically-based assay systems have been applied to the 
detection of specific venom and also to the detection of specific venom antibodies. These include 
immunodiffusion, immunofluorescence, haemagglutination, immunoelectrophoresis, radioimmunoassay 
(RIA), enzyme-linked immunosorbent assay (ELISA/EIA), and optical immunoassay, as well as the 
possible future applications of PCR and antibody microarrays in this respect. 
An agar-stabilised precipitation test was first used [11] to detect king cobra (Ophiophagus hannah) 
venom in excised bite site tissue and, later, gel immunodiffusion was used to detect the venoms from 
four common Nigerian snakes in wound aspirates, blister fluid, sera, and urine samples from 
envenomed patients [12]. Although generally successful in detecting specific venom, the system was 
not sensitive enough to detect venom in sera and was, therefore, of limited use. 
Immunofluorescence has been used to detect specific venom in tissue samples but not in body  
fluids [13]. Passive haemagglutination of sheep red cells sensitised to venom by the bis-diazo 
benzidine coupling procedure was used to demonstrate both venom and antivenom at high dilutions  
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in a test system but problems included instability of the coupling agent and imprecise end-point 
determination [14]. More recently a single-bead-based immunofluorescence assay has been developed 
for the detection of venom with a detection sensitivity of 5–10 ng/mL within a 3 h assay time [15].  
Immunoelectrophoresis was also used but was found to be unlikely to be of practical use in the 
routine assay of venom and venom antibodies owing to the high levels of common precipitating bands 
between venoms and antibodies of closely related species [16,17]. 
Radioimmunoassay [2,18,19] was used to detect venom in the serum of envenomed animals and 
patients but, although highly sensitive, the method proved to be impractical in patients as well as being 
very expensive, requiring specialised and elaborate reading equipment for measuring isotope levels in 
addition to the problems related to the short half-life of 125I. It was stressed that its use was primarily as 
a research tool [3]. 
Theakston and colleagues [1] first reported the use of enzyme-linked immunosorbent assay 
(ELISA) or EIA (enzyme immunoassay), using the double sandwich technique performed in 96 well 
Microtitre plates [20] for the detection of specific venom and the indirect method for detection of 
specific antibody (including antivenom) in the blood of envenomed victims. The principle of the 
technique is based on the linkage of soluble antigens to an insoluble solid phase (the wells of the plate) 
in such a way that the reactivity of the immunological components is retained. The double sandwich 
technique consists of binding specific venom antibody to the solid phase followed by a washing step to 
remove unbound material and subsequent addition of test material containing specific venom antigen. 
The detection of the venom-antibody complex thus formed is carried out, after further washing, by 
using specific antibody conjugated to an enzyme (such as horseradish peroxidase or alkaline 
phosphatase) (Figure 5a). Following a further washing stage, substrate specific for the enzyme is 
added, the amount of hydrolysis (colour change measured either visually or spectrophotometrically) 
being proportional to the amount of antigen (venom) present in the test sample. The test can also be 
used for detection and quantification of venom antigen in other body fluids such as urine and blister 
and wound aspirates. The indirect method for venom antibody (or antivenom) detection consists of 
binding antigen (immunologically active venom components) to the solid phase followed by 
incubation with the test sample. If the sample contains antibody against the specific antigen, the 
combination can be detected using anti-species immunoglobulin (e.g., horse, sheep, human, etc.) 
conjugated to the enzyme marker (Figure 5b). In this case the amount of hydrolysis is proportional to 
the amount of antibody present. In order to estimate the amounts of venom or venom antibody in the 
test sample the results (colour intensity) are compared with a standard curve set up on the same plate 
as the test samples. The basic principle of the method is shown in Figure 5. The sensitivity of the 
venom assay is in the region of 1 ng/mL serum, but using a modification of the EIA using a 
biotin/avidin combination the sensitivity can be even further increased [21]. For ease of sample 
collection in the field, whole blood samples can be placed on filter paper and dried; the blood is  
then eluted off with phosphate buffered saline in the laboratory and the EIA carried out on the  
eluate [22,23]. Pre-coated plates can be stored for later use and incubation times can be further 
reduced, permitting a total assay time of less than 3 hours although this is still not rapid enough for the 
clinician to decide on whether or not to treat the patient with antivenom. 
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Figure 5. (a) Detection of venom by EIA (ELISA): (1) Well of microtitre plate is coated 
with specific venom antibody IgG (or other immunoglobulin fragment such as Fab or 
F(ab/)2); (2) Patient’s sample containing specific venom is added to the well and binds to 
the antibody; (3) Patient’s sample containing a different venom is added and the venom is 
not recognised by the antibody and therefore does not bind; (4) In the positive sample the 
antigen/antibody complex is detected using enzyme-labelled antibody IgG; (b) Detection 
of venom antibody by EIA: (1) Plate is coated with venom; (2) Patient’s sample  
containing specific venom antibody added and binds to the venom; (3) In negative sample 
no binding occurs; (4) In the positive sample, venom/antibody complex is detected using  
enzyme-labelled anti-species IgG. It should be noted that there is a washing step between 
each stage of the assay to remove unbound components.  
 
Ho and colleagues [24] modified EIA by using a specific blocking system thus decreasing the 
problem of non-specific false positive reactions. Later, modifications of the EIA were developed [5] 
which were capable of detecting venom, antivenom, and venom-antivenom complexes; these assays 
investigated the problems associated with poor sensitivity and the occurrence of false positive results 
arising from high background absorbance [25]. 
More recently a specific and sensitive optical immunoassay (OIA) for venom detection was 
developed; this was similar to EIA but based on the principle of the detection of physical changes in 
the thickness of a molecular film resulting from specific binding events on an optical silicon chip [26]. 
The reflection of white light through the thin film results in destructive interference of the light from 
gold to purple-blue depending on the thickness of the thin film formed or the amount of venom in the 
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test sample. A prototype test kit for the simultaneous identification of the snake species causing 
envenoming and the semi-quantitative detection of venoms from four medically-important snakes from 
Vietnam was developed and was found to be capable of detecting venom in blood, plasma, urine, 
wound and blister aspirates, and tissue homogenates. The sensitivity of the test was claimed to be 
double that of EIA and the time taken to perform the assay was 33 min. 
Suntrarachun and colleagues [27] were the first group to investigate the use of the polymerase chain 
reaction (PCR) to distinguish the venom of the Thai cobra (Naja kaouthia) from the venoms of other 
Thai species using an experimental mouse model. In this early study, the sequences of nucleotide 
primers for the cobrotoxin-encoding gene from the Chinese cobra (Naja atra) were chosen because, at 
that time, the sequences of N.kaouthia were still unknown. In 2005, mitochondrial DNA (mtDNA) 
sequences from dried snake venom were used [28] and a DNA barcoding system for the precise 
identification of venoms was also developed. The group proposed the use of mtDNA for PCR to 
identify venoms which could overcome some problems encountered with methods such as EIA, 
although a sizeable venom sample would be required to extract a sufficient quantity of mtDNA; also 
one would need to decide exactly what to PCR [29]. It may not be a practical system at present because 
of the very small amounts of venom (nanogram quantities) present in the blood of snake bite victims. 
The use of antibody microarrays has also been proposed for detecting specific venoms but, to our 
knowledge, these have not yet been investigated in this respect. To be able to succeed, two key 
elements are necessary, namely a unique specific antigen in the venom and a unique antibody 
(monoclonal antibody) representing the unique protein in the venom of interest. From a proteomics 
point of view, it is known that there are unique peptide spectra that represent a sequence found only in 
a certain protein, which could then be only in a specific venom. The key is to select the correct protein 
and then the right peptide and hope that a monoclonal antibody can be made against it and that it 
would then bind an epitope in a native protein. This would be possible in principle but has not yet been 
achieved as far as we are aware [29]. 
4. Major Roles of Enzyme-linked Immunosorbent Assay (ELISA) or Enzyme Immunoassay 
(EIA) in Venom Research 
4.1. Accurate Retrospective Diagnosis: Which Snake is Responsible for the Accident? 
This is the most important direct role of EIA. As stated earlier it is frequently difficult to determine 
the species of the snake responsible for the bite. This means that the clinician may have problems in 
deciding on which antivenom to administer; if he or she cannot decide, then a polyspecific antivenom 
will be given which is produced by hyperimmunising animals (usually horses but sheep, goats, and 
even dogs and rabbits have also been used) with a mixture of different venoms obtained from snakes 
within a particular geographical region. In this situation more immune globulin is required than if a 
monospecific antivenom (antibody raised using a single venom) is used. This may result in the patient 
receiving more potentially reactive immunoglobulin causing a higher incidence of early anaphylactic 
reactions due to the presence of immunoglobulin aggregates (Fab or F(ab/)2) causing the uncontrolled 
release of histamine from mast cells. Sometimes the victim may also be at an increased risk of late 
serum sickness reactions caused by the production of humoral antibodies against the antivenom.  
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4.1.1. Validation 
In order to be able to depend on the results of venom immunoassay, it is vital first to validate the 
test. This is carried out by performing the venom assay on a number of serum samples from victims 
envenomed by different snake species. It is obviously essential that samples are assayed blind, the 
technician having no prior knowledge of the snake species responsible for the accident. The assay is 
carried out against the venoms from all species of venomous snakes known to be present in the study 
region. Once all the assays are complete, the results are compared with the taxonomically-identified 
snakes responsible for each accident. The study shown in Table 1 was performed in Amazonian Ecuador 
by our group. Each sample was assayed against the venom of four snake species known to occur in the 
study area (Shell Pastaza, Southern Ecuador). As the snakes here are closely related species, their 
venoms contain many common antigens resulting in cross reactivity in the EIA. The snake species 
responsible for the bite in each case is therefore obtained by selecting the result which yields the 
highest antibody titre. In 95% of cases, it can be seen that the results obtained by EIA using this 
criterion agreed with the snake species brought. 
Table 1. Retrospective diagnosis in Ecuador in 57 cases of venomous snakebite. 
Species Snakes brought Samples EIA positive Venom levels 
(range ng/mL) 
Bothrops atrox 26 26 (100%) 3-466 
B.bilineatus 25 24 (96%) 22-421 
Porthidium 
hyoprora 
1 1 350 
B.microphthalmus 1 No assay developed 5 * 
B.taeniatus 4 3 (75%) 23-225 
Non venomous 2 0 - 
Total venomous 57 54 (95%)  
Note: * levels measured in B.atrox venom assay. 
In another region of Eastern Ecuador, the Waorani tribe suffer a high mortality rate following  
snake bite due to their mode of living, hunting for food prey in the forest canopy using long blow  
pipes and poisoned darts (Figure 6). During a survey of health and disease among this population  
of 612 individuals in 1978 it was estimated that 4.9% of all deaths are due to snake bite, over 45% had 
experienced at least one bite and almost 95% of the male population had been bitten more than  
once [30,31]. 
4.1.2. Application  
The identification of the biting species by both lay and many medical personnel is notoriously 
inaccurate. Individuals involved at the time of the accident almost invariably describe the snake 
responsible as being “large and black”. EIA enables the reliable and objective determination of the 
species causing envenoming.  
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Figure 6. Waorani Indians of eastern Ecuador. About 5% of this tribal group die as a 
consequence of to snake bite (courtesy James W Larrick). 
 
In North-Central Nigeria (Bambur and Kaltungo, Benue valley) bites by the carpet viper  
(Echis ocellatus) are extremely common but the puff adder (Bitis arietans) and the spitting cobra  
(Naja nigricollis) are also implicated in this region. We found that immunodiagnosis in 37 consecutive 
admissions to one hospital 32 were positive for the venom of E.ocellatus, two for that of B.arietans 
and three for the venom of the relatively harmless night adder (Causus maculatus) [32].  
Sri Lanka has one of the highest incidences of snake bite in the world (incidence exceeding 
400/100,000 population/year and mortality 6/100,000/year). Our study in this country revealed  
that out of 94 consecutive hospital admissions in Anuradhapura General Hospital 36 (73% of EIA 
venom-positive cases) had been envenomed by Russell’s viper (Daboia russelli pulchella), five (10%) 
by the Indian cobra (N.naja), five (10%) by the Indian krait (Bungarus caeruleus) and three (6%) by 
the hump-nosed viper (Hypnale hypnale). Forty-five patients (48%) showed no signs of either local or 
systemic envenoming in spite of reporting bites [33]. This supports the observation that about half of 
snake bite victims receive little or no envenoming. 
In Thailand in 1982 we demonstrated that of 82 cases of bites by venomous snakes, 44 were caused 
by the Thai cobra (N.kaouthia) and one by the banded krait (B.fasciatus) [34]. The latter patient bitten 
by B.fasciatus died because he had been treated with the wrong monospecific “cobra” antivenom. 
Further studies in southern Thailand confirmed the diagnosis of envenoming by the Malayan pit viper 
(Calloselasma rhodostoma) in 23 of 46 systemically envenomed patients [7,35].  
Likewise in Bangladesh, later studies involving EIA accurately identified the species responsible for 
envenoming in 70 patients with bites by N.kaouthia admitted to a large hospital in Chittagong [36,37]. 
4.1.3. Rapid EIA 
For many years there has been a real need for a rapid test for venom detection which is reliable, 
effective and cheap. Such an assay system (e.g., EIA) would enable the clinician to decide which type 
of antivenom to use for treating a patient with systemic envenoming by a known snake species. For 
example, as mentioned earlier and for the reason given above, the most satisfactory antivenom for such 
a case would be a monospecific antivenom as a smaller volume would be utilised for effective therapy 
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compared with a polyspecific product (providing, of course, that such a monospecific product was 
available in the hospital dispensary). For example, in Nigeria in 1995 a monospecific E.ocellatus 
antivenom produced by Micropharm Ltd (Newcastle Emlyn, Wales, UK) was available and for the 
reasons given here was greatly preferable to a polyspecific Pasteur-Merieux Ipser Africa polyspecific 
(Bitis-Echis-Naja) antivenom [38]. We found that the monospecific antivenom was four-fold more 
effective in neutralising the venom of Nigerian E.ocellatus than the polyspecific product [38]. 
A Venom Detection Kit (VDK) based on the EIA test [1] was produced by CSL Diagnostics, 
Melbourne) for use in Australia [4,39] but this was not sensitive enough and was also extremely 
expensive (£34/test in1995). The test frequently was unable to detect specific venom in serum. A new 
Snake Venom Detection Kit (SVDK) has been developed more recently which is more sensitive and 
costs £50/test in 2013 (Williams D, personal communication 2013). 
The main problem with the VDK/SVDK is its cost which would be prohibitive in most developing 
countries where snake bite is a major problem. In Australia it is a useful test but its relative insensitivity, 
high levels of false positive results [5] and problems relating to cross reactivity [40,41] compared  
with the standard EIA also leave a lot to be desired although, as stated above, the new assay is  
more sensitive. It was concluded [42] that the SVDK may assist in regions where the range of 
medically-important snakes is too broad to permit the use of monospecific antivenoms. A further 
problem with this kit is that the venom from the bite site swab is the best for obtaining a reliable result; 
this is presumably because venom concentrations are the highest in this region. However, detection of 
the venom at the site does not necessarily mean that systemic envenoming has taken place. 
4.2. The Assessment of New and Existing Antivenoms; How Good is the Antivenom? 
This gives us the ability to objectively assess the efficacy of an antivenom by measuring the rate of 
clearance of venom from the circulation by any antivenom. It also permits the estimation of levels of 
circulating antivenom at any time after the start of antivenom administration. 
4.2.1. Preclinical Assessment of Antivenom Using in Vivo and in Vitro Tests 
Before an antivenom can be used to treat human cases of envenoming, it is essential to first test the 
product using assays approved by the World Health Organization (WHO) [43–45] and also mutually 
accepted by pharmaceutical companies and Ministries of Health. Such tests must not only examine the 
efficacy of an antivenom in neutralising the venoms against which it is raised but also, as far as is 
possible, test the product for safety. The main basic tests include lethality assays and lethality 
elimination assays carried out in experimental mice. Such tests involve injecting groups of five or six 
mice with gradually increasing amounts of venom by a predetermined route (usually intravenously) 
and establishing the amount of venom, which causes the death of half the animals within a group 
(median lethal dose or LD50 of the venom). A multiple of the LD50 (usually 2x, 3x, or 5x LD50) is then 
mixed with different amounts of the antivenom under test and the amount of antivenom which results 
in the survival of half the animals within a group is statistically calculated (median effective dose or 
ED50 of the antivenom). Other in vivo and in vitro tests commonly used include the elimination of 
venom-induced pathogenic effects such as those responsible for haemorrhage, coagulopathy (including 
defibrinogenation), and local necrosis [43,46–53]. In vivo tests involve major suffering to the 
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experimental animals involved and currently major efforts are being made to develop non-sentient or 
other alternative assays [54]. One proposed assay is the use of EIA which, in some circumstances can 
theoretically replace the standard lethality assay; in one study, good correlation (r = 0.96) was obtained 
between the rodent ED50 test and the ED50 as estimated using EIA [55]. It is obviously vital that any 
alternative assay must provide parallel, statistically comparable results to those obtained using the 
currently approved rodent-based assays. 
4.2.2. Clinical Assessment (Resolution of Clinical Signs in Patients) 
This is carried out by clinical observation of the envenomed victim. In systemic envenoming specific 
antivenom is the only effective therapeutic agent available. If used correctly, it can eliminate the signs 
of systemic envenoming when given hours or even days after the bite (Figure 2c). It has been shown to 
eliminate the systemic bleeding caused by the action of venom haemorrhagic metalloproteinases 
(Figure 2b) within 15–30 min of treatment and to normalise venom-induced coagulopathy (Figure 4a) 
within two to six hours in some cases of viper bite. Simple bedside tests such as the WBCT20  
(Figure 4b) [10] can be used on admission to assess whether or not the blood is coagulable (no 
antivenom required) or incoagulable due to the action of venom procoagulants or thrombin-like 
enzymes [56,57]. If the blood is incoagulable, then antivenom should be administered intravenously 
and the WBCT20 repeated at six hourly intervals until the clotting is normalised. If the blood remains 
incoagulable after the six hourly WBCT20, then a further dose of antivenom should be given and so on 
until permanent coagulability is achieved. This test is an excellent means of finding out whether a 
further dose of antivenom is required. The results obtained using this simple test have been demonstrated 
to correlate well with low blood fibrinogen levels [10]. Resolution of clinical signs is generally 
achieved more effectively and at lower dose when a monospecific, as opposed to a polyspecific, 
antivenom is administered. 
Resolution of venom-induced neurotoxicity is simple to record (e.g., elimination of ptosis and 
respiratory problems). Likewise the cessation of or inhibition of the progression of venom-induced 
rhabdomyolysis is easily recorded using tests for myoglobin in the urine [58] or estimating CPK-MM 
levels in the blood [59]. 
Antivenom is unlikely to be as dramatically effective in eliminating local signs of envenoming such 
as swelling and/or local necrosis. 
4.2.3. Pharmacokinetic Studies (Rate of Venom Elimination from the Circulation) 
A large amount of work has been carried out on the pharmacokinetics of envenoming using 
experimental animals, but relatively little on human victims of envenoming. 
In animals, one important study [60] assessed the effect of antivenom in experimentally envenomed 
rabbits. It was found that following an intramuscular injection of venom, the infusion of a set amount 
of antivenom caused a redistribution of venom antigens from the extravascular to the vascular space 
where access to antivenom resulted in neutralisation. It was also found that the difference in the effects 
of F(ab/)2 and Fab antivenom fragments could be explained by the different pharmacokinetics of the 
two fragments; the plasma distribution of venom when Fab antivenom was used was lower than with 
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F(ab/)2. It was concluded that the in vivo neutralisation of venom components by venom antibodies 
provides an experimental basis for the optimisation of antivenom treatment in humans. 
Many other animal-based studies have investigated the pharmacokinetics of envenoming and 
therapy [61–63] but all these used the intravenous route for venom administration which is inappropriate 
when in human victims venom is almost always either intradermally or intramuscularly. 
In our studies EIA has proved to be a very useful method for the objective assessment of antivenom 
efficacy and dosage [6,35]. It is now possible, as outlined earlier, to detect and quantify specific venom 
in the blood or other body fluids at any time after the bite (Figure 5a). In addition therapeutic 
antivenom can be detected and quantified at any time after antivenom administration (Figure 5b). 
Using this method it is also possible, in addition to detecting whole antivenom IgG, to detect specific 
antivenom IgG fragments, such as F(ab/)2 and Fab.  
An assay has recently been developed [64] which demonstrated the presence of venom-antivenom 
complexes (VAV) in in vitro mixtures of venom and antivenom. Measurement of these complexes 
indicated that in the case of so-called venom recurrence the VAV assay may indicate that there is only 
VAV present and not free venom. The authors of this study conclude that the VAV assay will provide 
a useful tool for the investigation of free and bound venom in envenomed patients. This may prove to 
be the case, but it should be borne in mind that these studies were performed in vitro and not in vivo. 
This system was used by the same group in patients envenomed by the Australian brown snake 
(Pseudonaja spp) but at the low venom concentrations that occurred, it was unable to detect VAVs [5]. 
Rojas and colleagues [65] studied the pharmacokinetics of antivenoms in different animal models. 
They concluded that equine immunoglobulins have different physico-chemical characteristics which 
give them the ability to access some body compartments where they can bind toxins. The antivenom 
concentration in these body compartments also depends on the species of animal used for antivenom 
production. As equine immunoglobulins are recognised in the homologous model (i.e., horses), or as 
foreign in heterologous models (e.g., cows, rabbits), immune mechanisms which recognise foreign 
protein are likely to accelerate the removal of heterologous antivenoms and, thus, affect the way in 
which the plasma concentrations of antivenom decreases over time. This will distort the pharmacokinetic 
predictions based on non-compartmental models.  
Figure 7 shows the effect of an efficient and inefficient antivenom in eliminating circulating venom. 
A variety of reasons may be responsible for the poor neutralising activity of an inefficient antivenom. 
These include a short elimination half-time which renders the antivenom incapable of adequate 
neutralisation of venom absorbed from the bite site (depot) subsequent to the initial venom 
antigenaemia or to the fact that the antivenom (e.g., imported Indian Haffkine antivenom used in Sri 
Lanka and in some African countries) is being produced using venom from snakes of geographical 
origin different from the area of use [33] and therefore has less neutralising potency.  
In Northern Nigeria the saw-scaled or carpet viper, E.ocellatus, is by far the commonest cause of 
snake bite with over 90% of bites in some areas being caused by this species. Figure 8 shows the 
clearance of venom from the circulation of a patient when an effective antivenom (Figure 8a) and a 
relatively ineffective antivenom (Figure 8b) is used. Results of immunoassay correlate with the 
elimination of venom-induced coagulopathy. 
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Figure 7. (a) The effect of an efficient antivenom and (b) an inefficient antivenom on 
clearance of circulating venom in systemically envenomed patients. Arrows indicate 
administration of antivenom. 
 
Figure 8. (a) Venom levels in a patient treated with one dose of SAIMR monospecific 
Echis antivenom and (b) in a patient treated with Behringwerke polyspecific antivenom. 
Arrow indicates antivenom given; C = clot, PC = partial clot, NC = no clot. 
 
In Sri Lanka bites by Russell’s viper, Daboia russelli pulchella, are common. Figure 9 shows the 
rapid clearance of venom from the circulation when a more effective monospecific Sri Lankan 
D.russelli pulchella (Therapeutic Antibodies) antivenom (Figure 9a), as opposed to an imported Indian 
polyspecific (Haffkine) antivenom (Figure 9b), is used. 
Bothrops jararaca is the commonest cause of snake bite in many regions of Brazil. Figure 10 shows 
venom (Figure 10a) and antivenom (Figure 10b) levels in 32 severely envenomed patients treated with 
the standard (Brazilian Health Service-approved) dose of eight vials (80 mL) of three different 
Brazilian antivenoms [66,67]. The results indicated that high levels of antivenom persisted for many 
hours after venom antigenaemia had been eliminated (as shown both clinically and by EIA). This 
therefore indicates (1) that the patients appear to be receiving more antivenom that was necessary to 
neutralise the circulating venom; (2) that it should be possible to reduce the dose to 20 mL or even to 
10 mL; and (3) in later studies this proved to be the case [68]. The obvious advantages in reducing the 
dose of antivenom are a decrease in the incidence of both early, life-threatening, anaphylactic reactions 
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and in delayed serum sickness reactions. This is accompanied by a decrease in the cost of therapy, 
especially important in a developing country. 
Figure 9. (a) Venom levels in a patient treated with one dose of monospecific Sri Lankan 
Russell’s viper antivenom and (b) in a patient treated with Indian Haffkine polyspecific 
antivenom. Arrow indicates antivenom given; C = clot, NC = no clot. 
 
Further studies carried out in Papua New Guinea [69], Thailand [7,70], Ecuador [57], and other 
parts of the world have indicated similar results. 
Figure 11 shows a large specimen of Echis pyramidum from Tunisia which caused severe systemic 
envenoming in a bite victim. Figure 12 indicates the sequence of events when the patient was treated 
with ineffective antivenom. Despite being given a total of 310 mL (six doses) of three different 
antivenoms (Behringwerke North and West Africa, Pasteur Bitis-Echis-Naja and monospecific South 
African SAIMR Echis antivenom) together with large amounts of fresh frozen plasma and 
concentrated clotting factors, venom antigenaemia and coagulopathy persisted for 12–13 days and the 
patient developed a haemolytic anaemia and mild renal dysfunction. Transient bilateral ptosis was also 
attributed to envenoming. This has never been reported before in cases systemically envenomed by 
members of the genus Echis. The venom of the snake responsible for the bite was immunologically 
distinct from that of Nigerian E. ocellatus, and apparently from other E.pyramidum “species” and it 
was clearly not neutralised by any of the three antivenoms which had been administered. Fortunately 
the patient recovered spontaneously two weeks after the bite [71].  
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Figure 10. (a) Venom and (b) antivenom levels in patients bitten by B.jararaca and treated 
with a single dose of eight vials (80 mL) of three Brazilian polyspecific Bothrops 
antivenoms. Arrow indicates antivenom given; C = clot, NC = no clot; unbroken line, 
Instituto Butantan antivenom; dotted line, Instituto Vital Brazil antivenom; broken line, 
Fundação Ezequiel Dias antivenom. 
 
Figure 11. Large specimen of Echis pyramidum from Tunisia responsible for a case of 
severe envenoming which was unresponsive to three different antivenoms with activity 
against other Echis spp. 
 
Toxins 2014, 6 1683 
 
 
Figure 12. Venom (unbroken line) and antivenom (dotted line) levels in a patient bitten by 
E.pyramidum from Tunisia and treated with six doses (310 mL total) of three different 
antivenoms with known activity against Echis spp. Arrow indicates antivenom given;  
C = clot, NC = no clot. 
 
4.3. Assessment of First Aid Measures 
EIA enables the testing of both accepted and traditional methods of first aid therapy. Many of these 
methods, used both in the past and currently, are of potential danger to the patient. 
4.3.1. Possible early First Aid Treatment with Antivenom in the Field 
A question has often been raised about whether antivenom administered by the easier intramuscular 
(im), as opposed to the intravenous (iv) route, is effective. If so, the im route could theoretically be 
used at the pre-hospital stage thus permitting earlier treatment of the patient with antivenom. Figure 13 
demonstrates that antivenom given by the im route does not permit high enough levels to be attained 
for therapeutic reversal of systemic symptoms of envenoming either in relation to time of entry into the 
circulation or to the levels achieved. The methodology used to carry out this hitherto unpublished 
study has been reported earlier only using anti-sheep Fab conjugate (see Section 3).  
These results are supported in experimental pharmacokinetic studies carried out on scorpion 
envenoming in rabbits both before and after antivenom therapy [72]. Following envenoming by the 
subcutaneous route, intravenous antivenom injection of an appropriate antivenom dose resulted in 
rapid, complete, and durable neutralization of toxins whereas an injection of the same dose of 
antivenom intramuscularly resulted in delayed venom neutralization. It was concluded that the 
antivenom must be injected intravenously to enable efficient immunotherapy.  
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Figure 13. Comparison of the absorption of one ampoule (10 mL) of ovine antivenom 
given by the iv route (unbroken line) with that given im (broken line) into the thigh muscle. 
Nine patients were used for each route of injection. Results are mean ± SEM. 
 
4.3.2. The Use of Tourniquets 
The use of tourniquets (Figure 2a) as a first aid measure in snake bite is highly controversial; 
tourniquets are frequently not applied correctly and, in bites involving a necrotising venom, they may 
result in the localisation of high venom concentrations at the bite site causing more severe local 
necrosis than would have otherwise occurred. Figure 14 indicates rapid release of venom into the 
circulation following tourniquet removal and the subsequent necessity for immediate antivenom 
therapy due to the development of clinical symptoms of envenoming. 
Figure 14. Venom levels (unbroken line) and antivenom levels (broken line) in a patient 
whose tourniquet was released on admission to hospital. Adm = time of admission to 
hospital; Rel = release of tourniquet; AV = point at which antivenom was given; C = clot; 
NC = no clot. 
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4.3.3. The Use of Local Remedies in Treatment of Snake Bite 
The use of local remedies in snake bite is also controversial with most traditional therapies being 
unlikely to be effective. One of these is the application of the “black snake stone” to the site of the bite, 
the aim being to extract the venom injected by the snake (Figure 15) via an absorbent medium. When 
the stone falls off, it is reckoned that the venom has been completely removed from the bite site. It is 
thought that such objects may be charcoaled bone but it is certain that other applications are also used. 
Before application of the stone, a cut is made at the bite site thus permitting the stone to adhere. In 
practice, in a patient with venom-induced coagulopathy and unstable blood vessels due to the action of 
venom procoagulants and haemorrhagins, this usually results in uncontrolled bleeding at the bite site. 
Figure 15. Snake stone applied to the site of the bite on the side of the right foot following 
a local incision at the site (courtesy, DA Warrell). 
 
We used an experimental mouse model where a measured minimum lethal dose of venom was 
injected intradermally and the snake stone was then applied to the bite site. Table 2 indicates that only 
a minute amount of venom was taken up by the stone when the absorbed venom was determined by 
EIA. This amount was definitely not enough to prevent the death of the animals, thus, indicating the 
lack of effectiveness of such a procedure. A more recent study also reported similar findings [73]. 
Table 2. Venom levels in serum, at injection (bite) site and in snakestone 24 h after a  
sub-lethal dose of venom in experimental mice. 
Sample 
Venom antigen concentration 
(mean ± SD (n = 5))
Serum 11.6 ± 5.6 ng/mL 
Bite site 21.6 ± 6.7 ng/mL 
Stone 0.3 ± 0.4 ng/mL 
Other devices such as suction applied to the site are also ineffective and, like the snake stone, may 
indeed cause adverse effects. In the case of suction devices, which are readily available on the market, 
there is a high risk of increasing the extent of the local venom-induced necrosis. 
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Other potential first aid measures could also be readily investigated using EIA. Indeed, Australian 
workers investigated the efficacy of the pressure immobilisation technique using RIA in experimental 
monkeys injected with tiger snake (Notechis scutatus) venom many years ago [74]. They found that 
when the injected limb was immobilised and a pressure of 55 mg Hg applied to the injection site, only 
very low levels of circulating venom were detected. Thus, venom movement into the general circulation 
can be effectively delayed for long periods by the application of a firm crepe bandage combined with 
an immobilising splint. The application of pressure alone did not delay venom movement. The same 
study could just as easily been carried out using EIA. Other methods such as the application of suction 
devices (considered to be clinically contraindicated as they are said to increase the problems of local 
venom-induced necrosis) and other devices designed to remove or flush out injected venom could also 
be readily easily assessed using EIA.  
4.4. Epidemiological Studies 
We found that using the EIA for detection of specific venom antibody, it is possible to examine the 
development of humoral venom antibodies [22] in previously envenomed individuals (Figure 16a). 
Levels are low until about eight days after the bite, rising rapidly to a peak at about 12 days and then 
falling rapidly. It is possible to also follow the levels of venom antibodies over time from the bite 
involving envenoming (Figure 16b) and to determine the snake responsible for envenoming in a 
previous bite [75]. Such a technique has application in epidemiological surveys although it must be 
stressed that a large control group (minimum 100) of subjects, never previously exposed to snake bite 
and from the same socio-economic group, must be used as controls. This is because, especially in 
developing countries where snakebite is a major problem, there may be interference in the assay due to 
the presence of non-specific antibodies (e.g., rheumatoid factor). The importance of adequate negative 
controls in such a system cannot be overstressed. For example, one study carried out by our group on 
the Waorani Indians of Eastern Ecuador (Figure 6) had limited value because controls from Caucasian 
subjects, as opposed to locals, were used to establish the baseline for the EIAc [76].  
Figure 16. (a) humoral venom antibody levels in a patient (LS) envenomed by E.ocellatus; 
(b) humoral antibody levels in patients at different times after the bite by vipers in Nigeria. 
Number of patients at each time range is given above each point (bars represent 2SEM). 
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Current epidemiological studies on snake bite leave a great deal to be desired. Health statistics 
grossly underestimate its incidence and importance in the rural tropics. Many studies are biased, 
relying on extrapolation of results from a single area of high snake bite incidence and mortality to a 
large geographical region [75] as mentioned below; others include only hospital data omitting any 
reference to snakebite victims who fail to reach hospital. However, if carried out properly, with an 
adequate number of appropriately selected controls (see above), EIA can contribute to the outcome of 
more accurate and meaningful epidemiological surveys. 
Studies carried out in 1979 in Nigeria using EIA in combination with detailed rural survey 
procedures [75] indicated that in northern, more densely populated savanna regions (estimated snake 
bite incidence 48/100,000/year; mortality 5.1%), the main species responsible was the spitting cobra 
(N.nigricollis) whereas in the generally less populated Benue Valley further south the annual snake 
bite incidence was estimated to be 497/100,000/year with a 12.2% mortality due mainly to the carpet 
viper (E.ocellatus). During this study 531 samples from previous bite victims were assayed for specific 
venom antibody and 210 (40%) of these were positive (65% against the venom of E.ocellatus, 13% 
against that of Bitis arietans, 11% against that of Causus maculatus, 8% against that of N.nigricollis 
venom, 3% against N.haje venom, and 0% against B.gabonica venom). These studies confirmed the 
importance of E.ocellatus reported by Warrell and Arnett in 1976 [77] and also demonstrated the 
contribution made by other venomous species particularly in milder cases of envenoming and even in 
severe cases in which victims with long distances to travel were not able to attend hospital or dispensary. 
On the basis of these figures from rural data it was estimated that snake bite resulted in about  
10,000 deaths/year in Northern Nigeria and, if extrapolated to include the entire West African savanna, 
this implied a mortality of about 23,000 deaths/year caused mainly by E.ocellatus. Warrell [78] rightly 
criticised these figures as being a major overestimation on the ground that unrepresentative areas to 
permit justifiable extrapolation were selected for the study. 
In a further study in French Guiana [79] the incidence of snake bite by defined species proved to be 
highest in the inhabitants of bush regions and lowest, as expected, in urban areas. Of 43 sera tested for 
specific venom antibody, 22 (51%) were positive for antibody against local snake venoms. 
Other studies combining mouse lethality tests with EIA have also demonstrated that humoral 
antibodies present in the serum of previous bite victims afford some degree of protection against 
subsequent exposure to venom [80]. 
4.5. Detection of Individual Venom Components 
As venoms contain a multiplicity of both toxic and non-toxic components, EIA permits the 
detection and quantification of the most important toxic components of a venom and their roles in the 
pathology and pharmacokinetics of envenoming. Figure 17 shows the detection of jararhagin [81], a 
haemorrhagic zinc metalloproteinase, in the venom of the Brazilian crotalid, B.jararaca. As expected, 
there is a precise relationship between the extent of systemic bleeding and the presence of jararhagin in 
the circulation of envenomed victims. For example, in 18 patients with systemic bleeding, venom 
levels were 357 ± 144 ng/mL serum (±2SEM) with haemorrhagin levels of 45 ± 16 ng/mL serum 
whereas in 15 patients with no systemic bleeding venom levels were 327 ng/mL ± 196 ng/mL and 
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haemorrhagin levels were 16  8 ng/mL. The differences in haemorrhagin levels were significantly 
different as would be expected. 
Figure 17. Venom levels (unbroken line) and jararhagin (haemorrhagin) levels (broken 
line) in serum from a patient. 
 
5. Conclusions 
In many cases of envenoming the snake responsible for the accident is not identified, a fact pointed 
out by Alistair Reid during the course of his research in Malaysia and West Africa, and this was one  
of his many reasons for encouraging the development of immunodiagnosis in Liverpool. Enzyme 
immunoassay was developed by his group at the Liverpool School of Tropical Medicine [1] and has 
proved to be of major use in the biodetection of venom and venom antibodies and in venom research 
generally. The main application of the EIA is in retrospective identification of the biting species. 
Although the assay can be shortened to produce a result within three hours, this is still not normally 
rapid enough to enable the clinician to act on its results. However, together with clinical observations, 
it enables patterns of envenoming to be established within and between the venomous species present 
in defined geographical areas.  
A rapid, sensitive, simple and affordable test is still required to enable the clinician to treat the 
patient with the correct monospecific (or polyspecific) antivenom at the bedside as soon as possible 
after admission to hospital. Such a kit has been developed in Australia but this is far too expensive for 
use in most developing countries where snake bite is a major problem of social, medical and economic 
importance [39]. The kit also has problems relating to decreased sensitivity. 
Other potentially useful and tested applications of enzyme immunoassay are described above. These 
include the ability to examine the pharmacokinetics of envenoming and therapy enabling the objective 
assessment of both new and existing antivenoms by looking at the rate of elimination of venom from 
the circulation in systemically envenomed patients. 
The method is appropriate for studying the efficacy, or lack of efficacy, of currently available and 
new first aid approaches. A great deal of damage occurs following the use of many such methods and, 
importantly, a visit to a traditional healer who applies such techniques drastically delays the arrival of 
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the patient at hospital where approved conventional treatment is available. On the other hand, there 
should also be awareness that perhaps a traditional pre-hospital treatment method may eventually be 
discovered which is appropriate and which is assessable using an immunoassay, although this seems 
unlikely at the present time. 
The use of enzyme immunoassay in epidemiological studies of snake bite is potentially extremely 
useful although the requirement for a powerful control (non-bitten) group of the same socio-economic 
background is stressed. There is a real need to determine the problem associated with snake bite and 
other bites and stings throughout the world. Funding bodies require reliable epidemiological information 
before they will consider supporting a project and in the field of venomous bites and stings this is 
sorely lacking. 
Other methods have been used and suggested to attempt to develop improved methods for studying 
the pharmacokinetics of envenoming and therapy in envenomed humans; these have been referred to 
earlier in this review. To date EIA has proved to be the method of preference for the reasons given 
previously (Section 2). 
It is now 50 years since Alistair Reid established the unit in Liverpool and in his honour it was 
renamed the Alistair Reid Venom Research Unit after his death in 1983. His major contributions to 
advances in the clinical treatment of envenoming by medically-important snakes and other animals [82], 
his astute observations on the mode of actions of a wide range of venoms including his role in the 
development of Arvin from the venom of the Malayan pit viper (Calloselasma rhodostoma), continues 
within the unit named after him. 
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